AstraZeneca Gets Exclusive Japan Rights For Dapagliflozin From BMS, To Co-Promote With Ono
This article was originally published in PharmAsia News
AstraZeneca, Bristol-Myers Squibb, and Ono Pharmaceuticals announced a commercialization and sales collaboration for the new SGLT2 inhibitor dapagliflozin used for type 2 diabetes.
You may also be interested in...
Artificial intelligence (AI) and machine learning took center stage at this year’s Radiological Society of North America meeting in Chicago, but the pervasiveness of AI tech in new product launches was further emphasized at the RSNA’s expanded AI Showcase exhibit.
Increasing savvy around cybersecurity issues is driving regulators and trade groups to update their approach to the area, speakers from the US FDA and the American Medical Association said at this week’s FDA/CMS Summit.